基础化工行业周报：合成生物学周报：北京发布百亿级合成生物计划，上海大力推进生物制造发展

Investment Rating - The industry investment rating is "Overweight" [1] Core Viewpoints - The report highlights the ongoing revolution in biotechnology, emphasizing the integration of synthetic biology into economic and social development to address major challenges such as health, climate change, resource security, and food security [1][3] - The "14th Five-Year Plan" for bio-economy development indicates a trillion-yuan market potential in synthetic biology, with significant government support and initiatives [1][3] - The synthetic biology index, which includes 62 listed companies across various sectors, has shown resilience, outperforming major indices like the Shanghai Composite Index [1] Summary by Sections Market Dynamics - The synthetic biology sector has seen a slight decline of 0.49% in the index during the week of November 18-22, 2024, while outperforming the Shanghai Composite Index by 1.42% [1][14] - Leading companies in the sector include Meiyingsen (+14%) and Yaxiang Co. (+10%), while companies like Zuming Co. (-13%) and Dongfang Shenghong (-12%) faced significant declines [1][14][16] Company Developments - Jiaao Environmental's bio-jet fuel project has successfully commenced production, with an expected annual output of 750,000 tons [18] - Yuantian Biological has launched a 300-ton production line, marking a significant milestone in its production capabilities [18] - Lif Biological's FDCA project is under public review, with a total investment of approximately 550 million yuan, aiming for a production capacity of 15,000 tons [19] Industry Financing - The report notes a surge in financing activities within the synthetic biology sector, with companies like Lingtai Bio and Metsera completing significant funding rounds [27][28] - Lingtai Bio raised over 100 million yuan in its A round, while Metsera secured $215 million in its B round, indicating strong investor interest in innovative biopharmaceutical solutions [27][28]